---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009419"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:31:25.835722+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock presents SRK-439 preclinical data showing lean mass preservation and initiates Phase 2 EMBRAZE trial

## Summary
- Preclinical DIO mouse study: SRK-439 with semaglutide preserved lean mass (26.4g vs 22.3g at 4 weeks, p<0.001) and increased relative lean mass (65.8%) after semaglutide withdrawal vs control (57.1%).
- SRK-439 attenuated fat mass rebound after semaglutide withdrawal: relative fat mass 18.0% vs 28.7% (p<0.01) and reduced inguinal and epididymal adipose weights.
- First participants dosed in Phase 2 EMBRAZE proof-of-concept trial of apitegromab in obesity patients on GLP-1 RA background therapy to assess lean muscle preservation.
- Data presented at ADA 84th Scientific Sessions on June 23, 2024, supporting SRK-439's potential for healthier weight management and long-term metabolic benefits.

## SEC filing metadata
- accession: 0001558370-24-009419
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837024009419/0001558370-24-009419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837024009419/srrk-20240624x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009419
- JSON: https://secwatch.observer/filing/0001558370-24-009419.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.